珂立苏联合CPAP治疗早产儿呼吸窘迫综合征

目的观察外源性肺表面活性物质联合n-CPAP治疗早产儿呼吸窘迫综合征的疗效。方法 32例患儿应用珂立苏及n-CPAP治疗,观察治疗后临床反应、血气变化、CPAP参数变化及疗效。结果应用珂立苏及n-CPAP后患儿呼吸困难、呻吟、发绀、吸凹征明显减轻或消失,CPAP参数均下调,用药前后pH、PaO2、PaCO2差异有统计学意义(P<0.05);无气胸、肺出血等并发症,32例均治愈出院。结论外源性肺表面活性物质珂立苏联合n-CPAP治疗早产儿呼吸窘迫综合征的疗效确切,可明显改善临床症状、血气指标及氧合状况。

Effect of pulmonary surfactant joint n-CPAP on respiratory distress syndrome in premature infants

Objective To observe the effects of pulmonary surfactant-Calf joint n-CPAP on respiratory distress syndrome of premature infants.Methods Thirty-two cases of premature infants with respiratory distress syndrome undergone the treatment with pulmonary surfactant-Calf joint n-CPAP.Then the clinical response,changes of blood gas index and CPAP parameter,and therapeutic effects were observed.Results After the treatment of pulmonary surfactant-Calf joint n-CPAP,the symptoms like dyspnea,retarded expiration,breath depressions sign and cyanosis were lessened and disappeared.The parameters of the CPAP were slowed down.The difference was significant when pH,PaO2,PaCO2 were compared with those of pre-medication(P<0.05).There were no complications like pneumothorax and pulmonary hemorrhage,and all 32 cases were cured.Conclusion It is effective to use pulmonary surfactant-Calf joint n-CPAP in the treatment of respiratory distress syndrome of premature infants,which can effectively improve the clinical symptom,blood gas index and status of oxygen.